公开(公告)号：US20210338636A1

公开(公告)日：2021-11-04

申请号：US17235468

申请日：2021-04-20

Applicant: Arena Pharmaceuticals, Inc.

Inventor： Alan Glicklich ,  Maria Matilde Sanchez Kam ,  William R. Shanahan

IPC: A61K31/403 ,  A61P3/10 ,  A61K9/48 ,  A61P29/00 ,  A61P35/00 ,  A61P17/10 ,  A61P37/02 ,  A61P19/02 ,  A61P17/06 ,  A61K9/20

Abstract: Provided are methods of treatment of a sphingosine 1-phosphate subtype 1 (S1P1) receptor-associated disorder comprising prescribing and/or administering to an individual in need thereof a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, in an amount equivalent to about 1.5 to about 2.5 mg of Compound 1, for example, a disease or disorder mediated by lymphocytes, an autoimmune disease or disorder, an inflammatory disease or disorder, ankylosing spondylitis, biliary cirrhosis, cancer, psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease, ulcerative colitis, type I diabetes, hypertensive nephropathy, glomerulosclerosis, myocardial ischemia-reperfusion injury, and acne.

公开(公告)号：US20240180870A1

公开(公告)日：2024-06-06

申请号：US18406732

申请日：2024-01-08

Applicant: Arena Pharmaceuticals, Inc.

Inventor： Alan Glicklich ,  Maria Matilde Sanchez Kam ,  William R. Shanahan

IPC: A61K31/403 ,  A61K9/20 ,  A61K9/48 ,  A61P3/10 ,  A61P5/00 ,  A61P17/06 ,  A61P17/10 ,  A61P19/02 ,  A61P29/00 ,  A61P35/00 ,  A61P37/02

CPC classification number: A61K31/403 ,  A61K9/4825 ,  A61P3/10 ,  A61P5/00 ,  A61P17/06 ,  A61P17/10 ,  A61P19/02 ,  A61P29/00 ,  A61P35/00 ,  A61P37/02 ,  A61K9/20

Abstract: Provided are methods of treatment of a sphingosine 1-phosphate subtype 1 (S1P1) receptor-associated disorder comprising prescribing and/or administering to an individual in need thereof a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta [b]indol-3-yl)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, in an amount equivalent to about 1.5 to about 2.5 mg of Compound 1, for example, a disease or disorder mediated by lymphocytes, an autoimmune disease or disorder, an inflammatory disease or disorder, ankylosing spondylitis, biliary cirrhosis, cancer, psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease, ulcerative colitis, type I diabetes, hypertensive nephropathy, glomerulosclerosis, myocardial ischemia-reperfusion injury, and acne.

公开(公告)号：US11896578B2

公开(公告)日：2024-02-13

申请号：US17235468

申请日：2021-04-20

Applicant: Arena Pharmaceuticals, Inc.

Inventor： Alan Glicklich ,  Maria Matilde Sanchez Kam ,  William R. Shanahan

IPC: A61K31/403 ,  A61P17/10 ,  A61P17/06 ,  A61P37/02 ,  A61P19/02 ,  A61P3/10 ,  A61P29/00 ,  A61P35/00 ,  A61K9/20 ,  A61K9/48 ,  A61P5/00

CPC classification number: A61K31/403 ,  A61K9/4825 ,  A61P3/10 ,  A61P5/00 ,  A61P17/06 ,  A61P17/10 ,  A61P19/02 ,  A61P29/00 ,  A61P37/02 ,  A61K9/20

Abstract: Provided are methods of treatment of a sphingosine 1-phosphate subtype 1 (S1P1) receptor-associated disorder comprising prescribing and/or administering to an individual in need thereof a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, in an amount equivalent to about 1.5 to about 2.5 mg of Compound 1, for example, a disease or disorder mediated by lymphocytes, an autoimmune disease or disorder, an inflammatory disease or disorder, ankylosing spondylitis, biliary cirrhosis, cancer, psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease, ulcerative colitis, type I diabetes, hypertensive nephropathy, glomerulosclerosis, myocardial ischemia-reperfusion injury, and acne.

公开(公告)号：US11007175B2

公开(公告)日：2021-05-18

申请号：US15541496

申请日：2016-01-06

Applicant: Arena Pharmaceuticals, Inc.

Inventor： Alan Glicklich ,  Maria Matilde Sanchez Kam ,  William R. Shanahan

IPC: A61K31/403 ,  A61P29/00 ,  A61P37/02 ,  A61K9/48 ,  A61P17/10 ,  A61P17/06 ,  A61P19/02 ,  A61P3/10 ,  A61P35/00 ,  A61K9/20

Abstract: Provided are methods of treatment of a sphingosine 1-phosphate subtype 1 (S1P1) receptor-associated disorder comprising prescribing and/or administering to an individual in need thereof a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoro-methyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, in an amount equivalent to about 1.5 to about 2.5 mg of Compound 1, for example, a disease or disorder mediated by lymphocytes, an autoimmune disease or disorder, an inflammatory disease or disorder, ankylosing spondylitis, biliary cirrhosis, cancer, psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease, ulcerative colitis, type I diabetes, hypertensive nephropathy, glomerulosclerosis, myocardial ischemia-reperfusion injury, and acne.